Tags

Type your tag names separated by a space and hit enter

Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment.
J Alzheimers Dis 2010; 22(3):985-91JA

Abstract

Recent years have witnessed an increasing interest in mild cognitive impairment (MCI), particularly as a possible prodromal stage of Alzheimer's disease (AD). Experimental and clinical data have suggested that cystatin C (CysC) is protective against the development of AD. In this study, we sought to cross-sectionally and longitudinally investigate the changes in plasma CysC levels in patients with MCI and whether the levels of this molecule might serve as a biochemical predictor of cognitive decline in this patient group. Cross-sectional analysis of baseline data showed a borderline significant difference in plasma CysC levels among the three study groups (Controls, n=63; AD, n=63; MCI, n=59) (p =0.032) that disappeared after post hoc analysis. Plasma CysC levels did not differ at baseline (t1) and at follow-up (t2) both in MCI patients that converted to AD (n= 32) and those that did not convert (n=27). However, a significant independent association between CysC at t1 and CysC at t2 was found in non-converters but not in converters MCI subjects. Moreover, when disease onset was evaluated in patients groups stratified on the basis of their CysC plasma levels, a significant anticipation of the conversion to dementia in MCI subjects with CysC levels below the median (CysC < 1067 ng/ml) (p =0.0011) was observed. Altogether, this work adds to the growing body of literature suggesting that CysC modulates the clinical expression of cognitive decline, and opens a new area of investigation of CysC as a therapeutic target for neurodegenerative disorders.

Authors+Show Affiliations

Proteomics Unit, IRCCS Centro S. Giovanni di Dio-FBF, Brescia, Italy. rghidoni@fatebenefratelli.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20858959

Citation

Ghidoni, Roberta, et al. "Plasma Cystatin C and Risk of Developing Alzheimer's Disease in Subjects With Mild Cognitive Impairment." Journal of Alzheimer's Disease : JAD, vol. 22, no. 3, 2010, pp. 985-91.
Ghidoni R, Benussi L, Glionna M, et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimers Dis. 2010;22(3):985-91.
Ghidoni, R., Benussi, L., Glionna, M., Desenzani, S., Albertini, V., Levy, E., ... Binetti, G. (2010). Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. Journal of Alzheimer's Disease : JAD, 22(3), pp. 985-91. doi:10.3233/JAD-2010-101095.
Ghidoni R, et al. Plasma Cystatin C and Risk of Developing Alzheimer's Disease in Subjects With Mild Cognitive Impairment. J Alzheimers Dis. 2010;22(3):985-91. PubMed PMID: 20858959.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. AU - Ghidoni,Roberta, AU - Benussi,Luisa, AU - Glionna,Michela, AU - Desenzani,Silvia, AU - Albertini,Valentina, AU - Levy,Efrat, AU - Emanuele,Enzo, AU - Binetti,Giuliano, PY - 2010/9/23/entrez PY - 2010/9/23/pubmed PY - 2011/6/10/medline SP - 985 EP - 91 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 22 IS - 3 N2 - Recent years have witnessed an increasing interest in mild cognitive impairment (MCI), particularly as a possible prodromal stage of Alzheimer's disease (AD). Experimental and clinical data have suggested that cystatin C (CysC) is protective against the development of AD. In this study, we sought to cross-sectionally and longitudinally investigate the changes in plasma CysC levels in patients with MCI and whether the levels of this molecule might serve as a biochemical predictor of cognitive decline in this patient group. Cross-sectional analysis of baseline data showed a borderline significant difference in plasma CysC levels among the three study groups (Controls, n=63; AD, n=63; MCI, n=59) (p =0.032) that disappeared after post hoc analysis. Plasma CysC levels did not differ at baseline (t1) and at follow-up (t2) both in MCI patients that converted to AD (n= 32) and those that did not convert (n=27). However, a significant independent association between CysC at t1 and CysC at t2 was found in non-converters but not in converters MCI subjects. Moreover, when disease onset was evaluated in patients groups stratified on the basis of their CysC plasma levels, a significant anticipation of the conversion to dementia in MCI subjects with CysC levels below the median (CysC < 1067 ng/ml) (p =0.0011) was observed. Altogether, this work adds to the growing body of literature suggesting that CysC modulates the clinical expression of cognitive decline, and opens a new area of investigation of CysC as a therapeutic target for neurodegenerative disorders. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/20858959/Plasma_cystatin_C_and_risk_of_developing_Alzheimer's_disease_in_subjects_with_mild_cognitive_impairment_ L2 - https://content.iospress.com/openurl?genre=article&amp;id=doi:10.3233/JAD-2010-101095 DB - PRIME DP - Unbound Medicine ER -